GSK to set up global vaccine center near FDA, NIH
This article was originally published in Scrip
Finding itself with nine sites across the US devoted to vaccines research and development after its mega swapping deal with Novartis, GlaxoSmithKline has decided to consolidate and create a global R&D center focused on those products in Maryland – the home of the FDA and the National Institutes of Health (NIH) and close to Washington, the seat of the US federal government.
You may also be interested in...
GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.